Latest news

A study funded by MSWA is examining factors influencing quality of life for people living with motor neurone disease (MND).

A new national study identified the need for greater emotional support at end of life for family carers of people with motor neurone disease (MND).

MSWA CEO will step down from his role in October after 19 years at the helm.

Today, on International Nurses Day we celebrate the impact our nurses have on the healthcare system and neurological care.

Ofatumumab (Kesimpta®) to be subsidised under the Pharmaceutical Benefit Scheme (PBS).

Today marks the start of Brain Awareness Week, a global campaign to spark interest, awareness and support for brain science.

As the leading organisation supporting Western Australians living with a neurological condition, MSWA is proud of a record contribution of $4m to neurological research this financial year making us Western Australia’s leading contributor to neurological research.

MSWA is proud to be Western Australia’s leading contributor to neurological research. This year, we are delighted to announce a new record contribution of $4m.

Ozanimod (Zeposia®) listed on the Pharmaceutical Benefits Scheme for the treatment of relapsing remitting MS (RRMS).

A recently published work by MSWA funded researcher Dr Lucinda Black from Curtin University suggests that dietary intake during childhood could affect the development of MS as an adult.

MSWA has begun construction of a new multipurpose $7m facility for people living with a neurological condition in Albany.